[go: up one dir, main page]

DK1366067T3 - Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed - Google Patents

Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed

Info

Publication number
DK1366067T3
DK1366067T3 DK02717581.9T DK02717581T DK1366067T3 DK 1366067 T3 DK1366067 T3 DK 1366067T3 DK 02717581 T DK02717581 T DK 02717581T DK 1366067 T3 DK1366067 T3 DK 1366067T3
Authority
DK
Denmark
Prior art keywords
proteins containing
expression technology
isotype antibody
antibody unit
hybrid isotype
Prior art date
Application number
DK02717581.9T
Other languages
English (en)
Inventor
Stephen D Gillies
Jeffrey Way
Kin-Ming Lo
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK1366067T3 publication Critical patent/DK1366067T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/53Hinge
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK02717581.9T 2001-03-07 2002-03-07 Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed DK1366067T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27409601P 2001-03-07 2001-03-07
PCT/US2002/007011 WO2002072605A2 (en) 2001-03-07 2002-03-07 Expression technology for proteins containing a hybrid isotype antibody moiety

Publications (1)

Publication Number Publication Date
DK1366067T3 true DK1366067T3 (da) 2012-10-22

Family

ID=23046749

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02717581.9T DK1366067T3 (da) 2001-03-07 2002-03-07 Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed

Country Status (17)

Country Link
US (2) US7148321B2 (da)
EP (1) EP1366067B1 (da)
JP (1) JP4234438B2 (da)
KR (2) KR20090010127A (da)
CN (1) CN1330664C (da)
AU (1) AU2002248571B2 (da)
BR (1) BR0207854A (da)
CA (1) CA2440221C (da)
DK (1) DK1366067T3 (da)
ES (1) ES2393733T3 (da)
HU (1) HUP0303428A2 (da)
MX (1) MXPA03008031A (da)
PL (1) PL206701B1 (da)
PT (1) PT1366067E (da)
RU (1) RU2003129528A (da)
WO (1) WO2002072605A2 (da)
ZA (1) ZA200307792B (da)

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1037927T3 (da) * 1997-12-08 2004-09-06 Emd Lexigen Res Ct Corp Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
RU2229305C2 (ru) * 1998-04-15 2004-05-27 Лексиген Фармасьютикэлс Корпорейшн Усиление иммунных ответов, опосредованных белками, слитыми из антитела и цитокина, посредством совместного введения ингибитора ангиогенеза
KR20020018197A (ko) * 1999-05-19 2002-03-07 추후보정 Fc 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
ATE316982T1 (de) 1999-08-09 2006-02-15 Lexigen Pharm Corp Mehrere zytokin-antikörper komplexen
EP1228214A2 (en) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
AU4314801A (en) 2000-02-11 2001-08-20 Lexigen Pharm Corp Enhancing the circulating half-life of antibody-based fusion proteins
US7517526B2 (en) * 2000-06-29 2009-04-14 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
DE10045591A1 (de) 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2440221C (en) 2001-03-07 2013-02-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Expression technology for proteins containing a hybrid isotype antibody moiety
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CN100503639C (zh) 2001-05-03 2009-06-24 默克专利有限公司 重组肿瘤特异性抗体及其应用
ATE542137T1 (de) 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
JP4494977B2 (ja) 2002-12-17 2010-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Gd2に結合するマウス14.18抗体のヒト化抗体(h14.18)およびそのil−2融合タンパク質
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
AU2004309050B2 (en) * 2003-12-30 2010-10-14 Merck Patent Gmbh IL-7 fusion proteins
CA2551916C (en) * 2003-12-31 2014-04-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung Fc-erythropoietin fusion protein with improved pharmacokinetics
US8420087B2 (en) 2004-01-05 2013-04-16 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
ATE443724T1 (de) * 2004-01-22 2009-10-15 Merck Patent Gmbh Antikrebs-antikörper mit reduzierter komplementfixierung
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP1769000B1 (en) * 2004-07-16 2014-12-24 Amgen Research (Munich) GmbH Expression-enhanced polypeptides
DE602005020837D1 (de) 2004-12-09 2010-06-02 Merck Patent Gmbh Il-7-varianten mit reduzierter immunogenität
CA2603408C (en) 2005-03-31 2018-08-21 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
PT1912675E (pt) * 2005-07-25 2014-05-09 Emergent Product Dev Seattle Moléculas de ligaçao especificas para cd37 e especificas para cd20
CN102628074B (zh) * 2005-08-19 2015-07-29 詹森生物科技公司 抗蛋白酶解的抗体制剂
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
CA2627444A1 (en) * 2005-10-24 2007-06-14 Centocor, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
PT2270050E (pt) 2005-12-30 2013-09-12 Merck Patent Gmbh Anticorpos anti-cd19 com imunogenicidade reduzida
CA2635615A1 (en) 2005-12-30 2007-07-12 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130
DK1966238T3 (da) * 2005-12-30 2012-07-16 Merck Patent Gmbh INTERLEUKIN-12P40-varianter med forbedret stabilitet
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
TW200738752A (en) 2006-01-31 2007-10-16 Bayer Schering Pharma Ag Modulation of MDL-1 activity for treatment of inflammatory disease
KR100934674B1 (ko) * 2006-03-30 2009-12-31 엘지전자 주식회사 비디오 신호를 디코딩/인코딩하기 위한 방법 및 장치
CN105177091A (zh) 2006-03-31 2015-12-23 中外制药株式会社 用于纯化双特异性抗体的抗体修饰方法
EP4001409A1 (en) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
WO2008003473A2 (en) * 2006-07-06 2008-01-10 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
US20100209385A1 (en) * 2007-03-30 2010-08-19 Mark Anthony Febbraio Treatment of obesity
WO2008143954A2 (en) * 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
JP5168538B2 (ja) * 2007-05-24 2013-03-21 アボットジャパン株式会社 抗体−抗体コンジュゲートと抗体測定系診断薬への応用
AU2013263716B2 (en) * 2007-06-01 2016-01-07 Gliknik Inc Immunoglobulin constant region FC receptor binding agents
CN107011445B (zh) 2007-06-01 2021-06-29 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
US8222016B2 (en) 2007-06-29 2012-07-17 Daiichi Sankyo Company, Limited Recombinant C-terminal α-amidating enzyme derivative
BRPI0814060A2 (pt) * 2007-07-06 2015-01-06 Trubion Pharmaceuticals Inc Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal
BRPI0814465B1 (pt) 2007-07-26 2021-11-23 Novagen Holding Corporation Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica
MX2010002683A (es) 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.
CA2978687C (en) 2007-09-26 2020-02-18 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
MX337081B (es) 2007-12-05 2016-02-10 Chugai Pharmaceutical Co Ltd Anticuerpo anti-nr10 y su uso.
US8574577B2 (en) * 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557242B2 (en) * 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8557243B2 (en) * 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8454960B2 (en) * 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
SG10201605629VA (en) * 2008-01-03 2016-08-30 Scripps Research Inst Antibody targeting through a modular recognition domain
CN102099377A (zh) 2008-04-11 2011-06-15 新兴产品开发西雅图有限公司 Cd37免疫治疗剂及其与双功能化学治疗剂的联合
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
EP2409991B1 (en) * 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
WO2010107109A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
EA201171259A1 (ru) 2009-04-22 2012-05-30 Мерк Патент Гмбх Антительные гибридные белки с модифицированными сайтами связывания fcrn
CA2761891A1 (en) 2009-05-15 2010-11-18 Chugai Seiyaku Kabushiki Kaisha Anti-axl antibody
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
JP2013509415A (ja) * 2009-10-29 2013-03-14 ヤンセン バイオテツク,インコーポレーテツド 抗体グリコシル化変異型
CN106399276B (zh) * 2009-11-02 2021-08-10 华盛顿大学 治疗性核酸酶组合物和方法
WO2011064758A2 (en) * 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
CN101870735B (zh) * 2010-06-02 2013-06-12 北京精益泰翔技术发展有限公司 一种新型高糖基化促红细胞生成素免疫融合蛋白
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
EP3543257A1 (en) 2010-07-28 2019-09-25 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
KR101333958B1 (ko) 2010-10-20 2013-11-27 주식회사 한독 인간 인터루킨-1 수용체 길항제-하이브리드 Fc 융합단백질
HRP20161531T1 (hr) * 2011-04-13 2016-12-30 Bristol-Myers Squibb Company Fc fuzijski proteini koji sadrže nove linkere ili aranžmane
EP3449933A1 (en) 2011-04-29 2019-03-06 University of Washington Therapeutic nuclease compositions and methods
CA2837169C (en) 2011-05-24 2021-11-09 Zyngenia, Inc. Multispecific complexes comprising angiopoietin-2-binding peptide and their uses
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
WO2012178137A1 (en) 2011-06-24 2012-12-27 Gillies Stephen D Light chain immunoglobulin fusion proteins and methods of use thereof
CA2843158A1 (en) * 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
US9382319B2 (en) 2011-09-26 2016-07-05 Jn Biosciences Llc Hybrid constant regions
CN103974977A (zh) * 2011-09-26 2014-08-06 Jn生物科学有限责任公司 杂交恒定区
WO2013112986A1 (en) * 2012-01-27 2013-08-01 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
BR112014026162A2 (pt) 2012-04-23 2017-10-03 Nrl Pharma Inc Proteína de fusão ou variante da mesma, molécula de ácido nucleico, vetor de expressão, célula hospedeira, animal não humano geneticamente modificado, planta geneticamente modificada, agente terapêutico para doenças melhoradas por lactoferrina, composição farmacêutica, e, método para preparar a proteína de fusão ou variante da mesma
US9931400B2 (en) 2012-09-12 2018-04-03 Samsung Electronics Co., Ltd. Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
CA2907181C (en) 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
WO2014144357A1 (en) 2013-03-15 2014-09-18 Merck Patent Gmbh Tetravalent bispecific antibodies
CN105324124A (zh) 2013-04-19 2016-02-10 赛腾制药 降低的血管渗漏综合征的细胞因子衍生治疗
US20150038682A1 (en) * 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
AU2013400609B9 (en) 2013-09-13 2020-03-05 Beone Medicines I Gmbh Anti-PD1 antibodies and their use as therapeutics and diagnostics
CA2925256C (en) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
HRP20192080T1 (hr) 2013-10-31 2020-02-07 Resolve Therapeutics, Llc Terapeutske fuzije nukleaza-albumine i postupci
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
RU2752424C2 (ru) 2014-02-10 2021-07-28 Мерк Патент Гмбх Направленное ингибирование tgf бета
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP6851200B2 (ja) 2014-03-05 2021-03-31 ユーシービー バイオファルマ エスアールエル 多量体Fcタンパク質
JP6744822B2 (ja) * 2014-04-03 2020-08-19 アイジーエム バイオサイエンシズ インコーポレイテッド 修飾j鎖
MX2016013149A (es) 2014-04-10 2017-04-27 Seattle Children's Hospital (Dba Seattle Children's Res Institute) Produccion de celulas t modificadas, mediante transposon bella durmiente, acoplada con seleccion por metotrexato.
MX360295B (es) * 2014-05-29 2018-10-29 Medimmune Llc Proteinas de fusion del ligando de ox40 (ox40l) y sus usos.
CN110156892B (zh) 2014-07-03 2023-05-16 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
CN106573052B (zh) 2014-07-22 2021-04-06 中美冠科生物技术(太仓)有限公司 抗pd-1抗体
NZ728749A (en) 2014-08-05 2023-06-30 Cb Therapeutics Inc Anti-pd-l1 antibodies
HUE051414T2 (hu) 2014-08-11 2021-03-01 Delinia Inc Módosított IL-2 változatok, amelyek szelektíven aktiválnak regulátor T sejteket, autoimmun betegségek kezelésére
CA2968382A1 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
SMT202000413T1 (it) 2014-11-21 2020-09-10 Bristol Myers Squibb Co Anticorpi nei confronti di cd73 e loro usi
WO2016133372A2 (ko) * 2015-02-17 2016-08-25 한미약품 주식회사 지속형 인슐린 또는 이의 아날로그 결합체
TWI759261B (zh) 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
RU2733492C2 (ru) * 2015-04-22 2020-10-02 Байоджен Ма Инк. Новые гибридные ActRIIB белки-ловушки лигандов для лечения заболеваний, связанных с мышечной атрофией
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2017004083A1 (en) * 2015-06-29 2017-01-05 The Regents Of The University Of California Methods of producing nucleic acid libraries and compositions and kits for practicing same
KR102649702B1 (ko) 2015-07-24 2024-03-21 글리크닉 인코포레이티드 향상된 상보체 결합을 갖는 규칙적으로 다형체화된 면역글로불린 fc 조성물을 생성하기 위한 인간 단백질 단편의 융합 단백질
CN108174604B (zh) 2015-08-07 2023-06-23 西雅图儿童医院(Dba西雅图儿童研究所) 用于实体瘤靶向的双特异性car t细胞
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
AU2016329197B2 (en) 2015-09-30 2021-01-21 Igm Biosciences, Inc. Binding molecules with modified J-chain
DK3356401T3 (da) 2015-09-30 2020-09-07 Igm Biosciences Inc Bindingsmolekyler med modificeret j-kæde
US20180271998A1 (en) 2015-12-04 2018-09-27 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CA3026420A1 (en) * 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
KR102531889B1 (ko) 2016-06-20 2023-05-17 키맵 리미티드 항-pd-l1 및 il-2 사이토카인
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018005954A2 (en) 2016-07-01 2018-01-04 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
CN109475536B (zh) 2016-07-05 2022-05-27 百济神州有限公司 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
SG11201901126UA (en) 2016-08-12 2019-03-28 Merck Patent Gmbh Combination therapy for cancer
TWI739887B (zh) 2016-08-19 2021-09-21 英屬開曼群島商百濟神州有限公司 使用包含btk抑制劑的組合產品治療癌症
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
WO2018079702A1 (ja) 2016-10-28 2018-05-03 株式会社Nrlファーマ ラクトフェリン/アルブミン融合タンパク質及びその製造方法
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
EP3538548A4 (en) 2016-11-08 2020-08-19 Delinia, Inc. IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11331372B2 (en) 2016-12-09 2022-05-17 Gliknik Inc. Methods of treating inflammatory disorders with multivalent Fc compounds
AU2017371179B2 (en) 2016-12-09 2022-07-14 Gliknik Inc. Manufacturing optimization of GL-2045, a multimerizing stradomer
MX2019006631A (es) 2016-12-12 2019-11-12 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Variantes quimericas de factores de transcripcion con sensibilidad aumentada a induccion por ligando de farmaco de expresion transgenica en celulas mamiferas.
EP3573989A4 (en) 2017-01-25 2020-11-18 Beigene, Ltd. CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
PE20200303A1 (es) 2017-05-24 2020-02-06 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer
TW202515616A (zh) 2017-06-26 2025-04-16 英屬開曼群島商百濟神州有限公司 抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途
CA3069119A1 (en) * 2017-07-07 2019-01-10 Hanmi Pharm. Co., Ltd. Novel therapeutic enzyme fusion protein and use thereof
MX2020002070A (es) 2017-08-22 2020-03-24 Sanabio Llc Receptores solubles de interferon y usos de los mismos.
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
US11319355B2 (en) 2017-12-19 2022-05-03 Xencor, Inc. Engineered IL-2 Fc fusion proteins
US11692042B2 (en) 2018-03-09 2023-07-04 Agenus Inc. Anti-CD73 antibodies and methods of use thereof
SG11202009010RA (en) 2018-03-15 2020-10-29 Chugai Pharmaceutical Co Ltd Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
CN112654637A (zh) * 2018-09-05 2021-04-13 株式会社Lg化学 包含可被o-糖基化的多肽区的融合多肽
MA53822A (fr) 2018-10-03 2021-08-11 Xencor Inc Protéines de fusion fc hétérodimères d'il -12
JP2022505923A (ja) 2018-11-01 2022-01-14 メルク パテント ゲーエムベーハー 抗tim-3抗体を投与する方法
EP3873611A1 (en) 2018-11-01 2021-09-08 Merck Patent GmbH Anti-tim-3 antibodies
AU2019409805A1 (en) 2018-12-21 2021-07-22 Ose Immunotherapeutics Bifunctional anti-PD-1/SIRPA molecule
US20230071889A1 (en) 2018-12-21 2023-03-09 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
WO2020127367A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Humanized anti-human-pd-1 antibody
WO2020127369A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
US12006345B2 (en) 2019-02-21 2024-06-11 Xencor, Inc. Untargeted and targeted IL-10 Fc-fusion proteins
EP3969119A1 (en) 2019-05-17 2022-03-23 Xencor, Inc. Il-7-fc-fusi0n proteins
DK3986920T3 (da) 2019-06-24 2025-06-10 Univ Stuttgart Tnfr2-agonister med forbedret stabilitet
CA3157024A1 (en) 2019-10-03 2021-04-08 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
US20240270831A1 (en) * 2021-06-17 2024-08-15 Fapon Biotech Inc. Chimeric immunoglobulin
US20230190799A1 (en) * 2021-07-21 2023-06-22 City Of Hope Chimeric antigen receptor t cells targeting cea and anti-cea-il2 immunocytokines for cancer therapy
US20240417453A1 (en) * 2021-10-27 2024-12-19 Anwita Biosciences, Inc. Il-2 fusion proteins, pharmaceutical compositions, and therapeutic applications
CN115028726B (zh) * 2022-03-31 2024-01-09 浙江特瑞思药业股份有限公司 一种抗pd-1纳米抗体及其应用

Family Cites Families (247)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US53539A (en) * 1866-03-27 Improvement in revolving fire-arms
US12789A (en) * 1855-05-01 Office
US193570A (en) * 1877-07-24 Improvement in washing-boards
US166877A (en) * 1875-08-17 Improvement in electric lights
US49227A (en) * 1865-08-08 Improvement in construction of railway trains and cars
US105294A (en) * 1870-07-12 Erasmus w
US3529A (en) * 1844-04-10 yvolfe
US81664A (en) * 1868-09-01 Island
US147311A (en) * 1874-02-10 Improvement in electric telegraphs
US192222A (en) * 1877-06-19 Improvement in watches
US44423A (en) * 1864-09-27 Improved screw for music-stools
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4469797A (en) 1982-09-23 1984-09-04 Miles Laboratories, Inc. Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US5082658A (en) * 1984-01-16 1992-01-21 Genentech, Inc. Gamma interferon-interleukin-2 synergism
EP0158198A1 (en) 1984-03-29 1985-10-16 Takeda Chemical Industries, Ltd. DNA and use thereof
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4667016A (en) * 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5679543A (en) 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
US5643565A (en) 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5359035A (en) 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
DE3712985A1 (de) 1987-04-16 1988-11-03 Hoechst Ag Bifunktionelle proteine
EP0237019A3 (en) 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
JPS63267278A (ja) 1986-03-14 1988-11-04 Toray Ind Inc インタ−フエロン結合体を暗号化する塩基配列
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4894227A (en) 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5508031A (en) 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
US4732683A (en) * 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
US5019368A (en) 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
ES2073394T3 (es) 1987-06-10 1995-08-16 Dana Farber Cancer Inst Inc Constructos de anticuerpos bifuncionales y su utilizacion para destruir selectivamente las poblaciones celulares.
US5064646A (en) 1988-08-02 1991-11-12 The University Of Maryland Novel infectious bursal disease virus
DE3880766D1 (de) 1987-09-02 1993-06-09 Ciba Geigy Ag Konjugate von interferon alpha mit immunglobulinen.
US5677425A (en) * 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
EP0308936B1 (en) 1987-09-23 1994-07-06 Bristol-Myers Squibb Company Antibody heteroconjugates for the killing of HIV-infected cells
PT88641B (pt) 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
AU2635088A (en) 1987-12-04 1989-06-08 Du Pont Merck Pharmaceutical Company, The Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク,インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
CA1341588C (en) 1988-01-26 2009-01-06 Michel Revel Human ifn-beta2/i1-6, its purification and use
US5120525A (en) 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
DE3812605A1 (de) 1988-04-15 1990-06-07 Leskovar Peter Dipl Ing Dr Hab Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
IT1217724B (it) 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
IE62463B1 (en) 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
IL91933A (en) 1988-10-11 1994-12-29 Univ Southern California Their immuno-bracelet and isophiles which are beneficial in increasing vascular permeability or blood supply to tumor or otherwise damaged tissue
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5242824A (en) 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
DE69019609T2 (de) 1989-07-07 1995-11-30 Takeda Chemical Industries Ltd Proteine und deren Herstellung.
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
EP0493418B1 (en) 1989-09-20 1997-04-23 Abbott Laboratories Method of producing fusion proteins
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
AU646822B2 (en) 1989-10-13 1994-03-10 Kirin-Amgen Inc. Erythropoietin isoforms
ATE368112T1 (de) 1989-12-22 2007-08-15 Hoffmann La Roche Zytotoxischer lymphozyten-reifefaktor 40kd untereinheit und monoklonale antikörper spezifisch dafür
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
JPH07507440A (ja) * 1990-03-02 1995-08-24 レプリゲン・コーポレーション 結合親和性を高めた抗体構築物
CA2078689C (en) 1990-03-20 2003-02-11 Sherie L. Morrison Chimeric antibodies with receptor binding ligands in place of their constant region
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
EP0541716A1 (en) 1990-07-27 1993-05-19 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0556328A4 (en) 1990-11-09 1994-06-08 Abbott Lab Bridging antibody fusion constructs
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
ATE218889T1 (de) 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
WO1992010755A1 (en) 1990-12-05 1992-06-25 Novo Nordisk A/S Proteins with changed epitopes and methods for the production thereof
US5709859A (en) 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
GB9105245D0 (en) 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
US6072039A (en) 1991-04-19 2000-06-06 Rohm And Haas Company Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
WO1993003157A1 (en) 1991-07-29 1993-02-18 Dana Farber Cancer Institute Plasmids for the rapid preparation of modified proteins
AU666866B2 (en) 1991-08-30 1996-02-29 Fred Hutchinson Cancer Research Center Hybrid cytokines
US20020037558A1 (en) 1991-10-23 2002-03-28 Kin-Ming Lo E.coli produced immunoglobulin constructs
US5376367A (en) 1991-11-22 1994-12-27 Immunex Corporation Fusion proteins comprising MGF and IL-3
US5277375A (en) * 1991-12-04 1994-01-11 The Procter & Gamble Company Spindle for use with compressed core wound paper products
US6627615B1 (en) 1991-12-17 2003-09-30 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
ES2215991T3 (es) 1992-04-01 2004-10-16 The Rockefeller University Procedimiento para la proliferacion (in vitro) de precursores de celulas dendriticas y su uso para producir inmunogenos.
AU687733B2 (en) 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
AU666388B2 (en) * 1992-05-26 1996-02-08 Immunex Corporation Novel cytokine that binds CD30
WO1993025673A1 (en) 1992-06-04 1993-12-23 The Regents Of The University Of California In vivo gene therapy with intron-free sequence of interest
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
CA2142007C (en) 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
DE4228839A1 (de) 1992-08-29 1994-03-03 Behringwerke Ag Verfahren zum Nachweis und zur Bestimmung von Mediatoren
DE69232604T2 (de) 1992-11-04 2002-11-07 City Of Hope Duarte Antikörperkonstrukte
EP0668777B2 (en) 1992-11-05 2011-02-09 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US5738849A (en) 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5543297A (en) 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5738852A (en) * 1993-04-20 1998-04-14 Solis Therapeutics, Inc. Methods of enhancing antigen-specific T cell responses
WO1994024160A2 (en) 1993-04-21 1994-10-27 Brigham And Women's Hospital Erythropoietin muteins with enhanced activity
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
AU6776194A (en) 1993-04-28 1994-11-21 Hybritech Incorporated Method for creating optimized regulatory regions affecting protein expression and protein trafficking
KR960701650A (ko) 1993-04-29 1996-03-28 찰스 엠. 브룩 에리트로포이에틴 유사체 조성물 및 방법(Eythropoietin analog compositions and methods)
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
CA2125763C (en) 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
WO1995002939A1 (en) 1993-07-16 1995-01-26 Sony Corporation Image pickup parameter recorder, image pickup method, and editing system
US5609876A (en) * 1993-08-09 1997-03-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide vaccines and associated methods for protection against feline leukemia virus
GB9316989D0 (en) 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
ZA946122B (en) 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
DE69521789T2 (de) 1994-02-01 2002-04-25 The United States Of Amerika Represented By The Secretary, Department Of Health And Human Fusionierte proteine die antikörper-teile und nicht-antikörper-teile enthalten
WO1995028427A1 (en) 1994-04-15 1995-10-26 Imclone Systems Incorporated Chimeric interleukin-3/mutein interleukin-6 lymphokine
BR9507479A (pt) 1994-04-26 1997-09-16 Childrens Medical Center Angipstantina e processo de uso para inibição de angiogenese
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
CA2190101A1 (en) 1994-05-13 1995-11-23 Donald Leonard Nicholas Cardy Improvements in or relating to peptide delivery
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
NZ292124A (en) 1994-07-29 1998-10-28 Smithkline Beecham Plc Il-4 antagonist comprising a fusion of a mutant il-4-antibody fragment
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5888773A (en) * 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
EP0706799B1 (en) 1994-09-16 2001-11-14 MERCK PATENT GmbH Immunoconjugates II
JP3429578B2 (ja) * 1994-10-31 2003-07-22 オリンパス光学工業株式会社 小型リアフォーカスズームレンズ
CA2205572A1 (en) 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5691309A (en) 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
ES2225874T3 (es) 1995-03-10 2005-03-16 Genentech, Inc. Activacion de receptor mediante gas.
US5719266A (en) 1995-03-17 1998-02-17 Eli Lilly And Company Anti-obesity proteins
AU5539596A (en) 1995-04-06 1996-10-23 Amylin Pharmaceuticals, Inc. Anti-obesity agents
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
WO1997000317A1 (en) 1995-06-07 1997-01-03 Osteosa Inc. Osteoclast growth regulatory factor
AU5893796A (en) 1995-06-07 1996-12-30 Novo Nordisk A/S Modification of polypeptides
GB9511935D0 (en) 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
EP0836479A2 (en) 1995-06-30 1998-04-22 Eli Lilly And Company Methods for treating diabetes
US6406689B1 (en) 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
US5854205A (en) 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
KR19990066981A (ko) 1995-10-23 1999-08-16 윌리엄 뉴우 치료용 맥관형성억제 조성물 및 방법
WO1997020062A1 (en) 1995-12-01 1997-06-05 University Of Massachusetts Il-12 p40 subunit fusion polypeptides and uses thereof
CN1154726C (zh) 1995-12-27 2004-06-23 基因技术股份有限公司 具长半衰期的ob蛋白质衍生物
US6620413B1 (en) * 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6080409A (en) 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US7063958B1 (en) 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
AU1952497A (en) 1996-02-13 1997-09-02 Regents Of The University Of California, The Novel antibody-cytokine fusion protein, and methods of making and using the same
US5756541A (en) 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
AU2527397A (en) 1996-03-13 1997-10-01 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
CA2205757C (en) 1996-05-30 2006-01-24 F. Hoffmann-La Roche Ag Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii)
US5922685A (en) 1996-06-05 1999-07-13 Powderject Vaccines, Inc. IL-12 gene therapy of tumors
JP2002514161A (ja) 1996-07-02 2002-05-14 バー イラン ユニバーシティー ガンおよび他の細胞増殖性疾患の治療に有用なレチノイルオキシ(置換)アルキレンブチレート
AU4075897A (en) 1996-08-16 1998-03-06 Roger Lallone A leptin binding protein and its use in methods for diagnosing and treating abnormalities of the endogenous leptin pathway
DK0826696T3 (da) * 1996-09-03 2002-09-23 Gsf Forschungszentrum Umwelt Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet
US5994104A (en) 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
IL130396A (en) 1996-12-20 2011-09-27 Amgen Inc OB fusion protein, nucleic acid sequence, vector, cell, process for protein production and pharmaceutical preparation
US6737057B1 (en) 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998046264A1 (en) 1997-04-11 1998-10-22 G.D. Searle & Co. Antagonistic anti-avb3 integrin antibodies
EP0977583B1 (en) 1997-04-17 2002-09-04 Amgen Inc. Compositions comprising conjugates of stable, active, human ob protein with immunoglobulin fc chain and methods
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
GB9712892D0 (en) 1997-06-20 1997-08-20 Eclagen Ltd Identification of mhc binding peptides
AU8182298A (en) * 1997-07-10 1999-02-08 Beth Israel Deaconess Medical Center Recombinant erythropoietin / immunoglobulin fusion proteins
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
DK1037927T3 (da) 1997-12-08 2004-09-06 Emd Lexigen Res Ct Corp Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering
CA2320403A1 (en) * 1998-02-25 1999-09-02 Lexigen Pharmaceuticals Corporation Enhancing the circulating half-life of antibody-based fusion proteins
US20030105294A1 (en) 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
RU2229305C2 (ru) 1998-04-15 2004-05-27 Лексиген Фармасьютикэлс Корпорейшн Усиление иммунных ответов, опосредованных белками, слитыми из антитела и цитокина, посредством совместного введения ингибитора ангиогенеза
BR9909677A (pt) 1998-04-17 2000-12-19 Lexigen Pharm Corp Intensificação de respostas imunológicas, mediadas por proteìna de fusão anticorpo-citocina, através de co-administração com inibidor de prostaglandinas
AU3655899A (en) * 1998-04-20 1999-11-08 Regents Of The University Of California, The Modified immunoglobulin molecules and methods for use thereof
EP1088888A4 (en) 1998-05-14 2005-03-16 Merck Patent Gmbh MERGED PROTEIN
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
AU4414099A (en) 1998-06-03 1999-12-20 Children's Medical Center Corporation Protein oligomer compositions comprising endostatin protein and methods of usingthe same
EP1088084B1 (en) 1998-06-15 2006-09-13 GTC Biotherapeutics, Inc. Erythropoietin analog-human serum albumin fusion protein
GB9814383D0 (en) 1998-07-02 1998-09-02 Cambridge Antibody Tech Improvements relating to antibodies
WO2000009560A2 (en) * 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1107989B1 (en) 1998-08-25 2010-03-31 Merck Patent GmbH Expression and export of angiostatin and endostatin as immunofusins
US6646113B1 (en) 1998-09-17 2003-11-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
US6335176B1 (en) * 1998-10-16 2002-01-01 Pharmacopeia, Inc. Incorporation of phosphorylation sites
EP1123313B2 (en) 1998-10-23 2018-01-10 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
DE69934967T2 (de) 1998-12-08 2007-12-06 Biovation Ltd. Verfahren zur verminderung der immunogenität von proteinen
WO2000040615A2 (en) 1999-01-07 2000-07-13 Lexigen Pharmaceuticals, Corp. EXPRESSION AND EXPORT OF ANTI-OBESITY PROTEINS AS Fc FUSION PROTEINS
WO2000066913A1 (en) 1999-04-30 2000-11-09 Peter Bortolin Power transmission apparatus
US6500641B1 (en) 1999-05-06 2002-12-31 Wake Forest University School Of Medicine Compositions and methods for identifying antigens which elicit an immune response
EP1177285A1 (en) 1999-05-07 2002-02-06 Genentech, Inc. Chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same
US6348192B1 (en) 1999-05-11 2002-02-19 Bayer Corporation Interleukin-2 mutein expressed from mammalian cells
KR20020018197A (ko) * 1999-05-19 2002-03-07 추후보정 Fc 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비
WO2000078334A1 (en) 1999-06-17 2000-12-28 University Of Maryland Biotechnology Institute Chimeric chemokine-antigen polypeptides and uses therefor
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US7067110B1 (en) * 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
NZ517372A (en) * 1999-07-29 2004-04-30 Medarex Inc Human monoclonal antibodies to HER2/neu
ATE316982T1 (de) * 1999-08-09 2006-02-15 Lexigen Pharm Corp Mehrere zytokin-antikörper komplexen
US20050202538A1 (en) 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
EP1228214A2 (en) * 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
AU4314801A (en) * 2000-02-11 2001-08-20 Lexigen Pharm Corp Enhancing the circulating half-life of antibody-based fusion proteins
CA2399866C (en) 2000-02-24 2011-05-10 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
JP2004528001A (ja) 2000-05-12 2004-09-16 ネオーズ テクノロジーズ, インコーポレイテッド インビトロにおけるフコシル化組換えグリコペプチド
US7517526B2 (en) 2000-06-29 2009-04-14 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AU2002241922B2 (en) 2001-01-17 2007-10-25 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
JP2004525621A (ja) 2001-01-18 2004-08-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング グルコセレブロシダーゼ活性を有する二機能性融合タンパク質
JP4279554B2 (ja) 2001-02-19 2009-06-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング T細胞エピトープの識別方法および低減された免疫原性を有する分子の製造方法
MXPA03007323A (es) 2001-02-19 2003-12-12 Merck Patent Gmbh Proteinas artificiales con inmunogenicidad reducida.
CA2440221C (en) 2001-03-07 2013-02-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Expression technology for proteins containing a hybrid isotype antibody moiety
BR0208041A (pt) 2001-03-15 2004-02-25 Merck Patent Gmbh Interferon beta modificado com imunogenicidade reduzida
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CN100503639C (zh) 2001-05-03 2009-06-24 默克专利有限公司 重组肿瘤特异性抗体及其应用
JP2005507870A (ja) 2001-08-13 2005-03-24 ユニバーシティ・オブ・サザン・カリフォルニア 低毒性のインターロイキン−2突然変異体
ATE542137T1 (de) * 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
CA2479212A1 (en) 2002-03-15 2003-09-25 Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
JP4494977B2 (ja) * 2002-12-17 2010-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Gd2に結合するマウス14.18抗体のヒト化抗体(h14.18)およびそのil−2融合タンパク質
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
AU2004309050B2 (en) * 2003-12-30 2010-10-14 Merck Patent Gmbh IL-7 fusion proteins
CA2551916C (en) 2003-12-31 2014-04-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung Fc-erythropoietin fusion protein with improved pharmacokinetics
ATE443724T1 (de) 2004-01-22 2009-10-15 Merck Patent Gmbh Antikrebs-antikörper mit reduzierter komplementfixierung
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
DE602005020837D1 (de) * 2004-12-09 2010-06-02 Merck Patent Gmbh Il-7-varianten mit reduzierter immunogenität
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
CA2635615A1 (en) 2005-12-30 2007-07-12 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130
PT2270050E (pt) 2005-12-30 2013-09-12 Merck Patent Gmbh Anticorpos anti-cd19 com imunogenicidade reduzida
DK1966238T3 (da) 2005-12-30 2012-07-16 Merck Patent Gmbh INTERLEUKIN-12P40-varianter med forbedret stabilitet
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
WO2008003473A2 (en) * 2006-07-06 2008-01-10 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of il-2 mediated immune responses

Also Published As

Publication number Publication date
ES2393733T3 (es) 2012-12-27
US20030044423A1 (en) 2003-03-06
BR0207854A (pt) 2004-08-24
PL206701B1 (pl) 2010-09-30
KR100900176B1 (ko) 2009-06-02
US8066994B2 (en) 2011-11-29
PL366981A1 (en) 2005-02-07
RU2003129528A (ru) 2005-04-10
ZA200307792B (en) 2004-07-06
CN1330664C (zh) 2007-08-08
CA2440221C (en) 2013-02-05
EP1366067A2 (en) 2003-12-03
CA2440221A1 (en) 2002-09-19
EP1366067A4 (en) 2005-07-20
WO2002072605A2 (en) 2002-09-19
AU2002248571B2 (en) 2007-01-18
WO2002072605A3 (en) 2002-11-14
PT1366067E (pt) 2012-11-29
CN1509293A (zh) 2004-06-30
KR20030092015A (ko) 2003-12-03
US20060263856A1 (en) 2006-11-23
MXPA03008031A (es) 2003-12-04
US7148321B2 (en) 2006-12-12
KR20090010127A (ko) 2009-01-28
HUP0303428A2 (hu) 2004-01-28
JP4234438B2 (ja) 2009-03-04
JP2004525630A (ja) 2004-08-26
EP1366067B1 (en) 2012-09-26

Similar Documents

Publication Publication Date Title
DK1366067T3 (da) Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
DE60222658D1 (de) Monoklonaler anti-cd-40-antikörper
EE200300179A (et) Humaniseeritud LT-ß-R-i vastased antikehad
DE60212226D1 (de) Tonerbehälter
ATE480564T1 (de) Monoklonaler anti-mensch-tenascin-antikörper
EE200300569A (et) CD44v6-spetsiifilised antikehad
DK1164375T3 (da) Assay til antitransglutaminaseantistoffer
DK1392722T3 (da) Fremgangsmåde vedrörende echinocandiner
NO20044145L (no) Assay for anti-INGAP antistoffer
FI20002262L (fi) Menetelmä proteiinin rakenteen muuttamiseksi
FI20011055L (fi) Heveiiniä sitovat monoklonaaliset vasta-aineet
DK1171470T3 (da) Antistoffer over for placentaprotein 13
EE200300377A (et) Loomulikud HI-viiruse vastased antikehad
ITPD20000192A0 (it) Anticorpi policlonali
NO20035107D0 (no) Antistoffer som er spesifikke for CD44V6
ATE535259T1 (de) Immunogener, monoklonaler antikörper
ATE480262T1 (de) Fusionsproteine
UA4910S (uk) Упаковка для козінаку
UA5193S (uk) Пакування для електроламп розжарювання
UA5385S (uk) Пакування для електроламп розжарювання
UA5880S (uk) Флакон для косметичних засобів
UA5107S (uk) Упаковка для кетчупа
GB0121727D0 (en) Monoclonal antibodies
DE60238559D1 (de) Criptospezifische antikörper
UA6596S (uk) Матеріал для упаковування дріжджів